Treating COVID-19—off-label drug use, compassionate use, and randomised clinical trials during pandemics

JAMA

24 March 2020 - In the 2014 Ebola outbreak, close to 30 000 individuals developed Ebola viral disease, and numerous therapies were tested against this virus, including chloroquine, hydroxychloroquine, favipiravir, brincidofovir, monoclonal antibodies, antisense RNA, and convalescent plasma, among many others. 

With such a large number of therapeutic interventions given to affected patients, the goal was to determine which was efficacious against Ebola. 

Ultimately, none proved to be efficacious or safe.

Read JAMA Viewpoint

Michael Wonder

Posted by:

Michael Wonder